Extract to table

This letter summarizes the documents that were executed, identifies the conditions precedent to funding that remain outstanding, and sets forth the action items that must be completed in order to achieve funding on the anticipated timeline

Below is a summary of the deliverables that remain outstanding as of the Signing Date and must be satisfied on or prior to the anticipated Funding Date of March 13, 2026

4 IP Security Agreement Recording The short-form Patent and Trademark Security Agreement described in Section 2(3) above must be recorded with the USPTO to perfect the Collateral Agent's security interest in GenomeDx's registered patent and trademark portfolio

10 Payment of Fees The following fees and expenses must be paid on or prior to the Funding Date

GenomeDx must maintain a minimum cash balance of $3,000,000 at all times, tested as of the last business day of each calendar month